Schrodinger, Inc. (SDGR) stock

SDGRNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 12/3079% above fair value

$30.85−0.67 (-2.13%)

Close on Nov 12, 2026Market cap $2.31BP/E –Yield –

Schrodinger ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Schrodinger's ebitda for the twelve months ending Sep 30, 2026 was -$127.77M. For fiscal 2025 it was -$160.87M. The highest annual figure on record is -$35.08M in fiscal 2019.

Annual ebitda

Period	Period end	Value	Change
FY2025	Dec 31, 2025	-$160.87M	–
FY2024	Dec 31, 2024	-$203.14M	–
FY2023	Dec 31, 2023	-$171.90M	–
FY2022	Dec 31, 2022	-$142.47M	–
FY2021	Dec 31, 2021	-$108.60M	–
FY2020	Dec 31, 2020	-$57.26M	–
FY2019	Dec 31, 2019	-$35.08M	–

Quarterly ebitda

Change is against the same quarter a year earlier.

Period	Period end	Value	Change
Q3 FY2026	Sep 30, 2026	-$24.67M	–
Q2 FY2026	Jun 30, 2026	-$40.06M	–
Q1 FY2026	Mar 31, 2026	-$47.32M	–
Q4 FY2025	Dec 31, 2025	-$15.72M	–
Q3 FY2025	Sep 30, 2025	-$44.48M	–
Q2 FY2025	Jun 30, 2025	-$51.37M	–
Q1 FY2025	Mar 31, 2025	-$49.30M	–
Q4 FY2024	Dec 31, 2024	-$18.95M	–
Q3 FY2024	Sep 30, 2024	-$66.86M	–
Q2 FY2024	Jun 30, 2024	-$51.33M	–
Q1 FY2024	Mar 31, 2024	-$66.00M	–
Q4 FY2023	Dec 31, 2023	-$28.27M	–
Q3 FY2023	Sep 30, 2023	-$54.92M	–
Q2 FY2023	Jun 30, 2023	-$59.97M	–
Q1 FY2023	Mar 31, 2023	-$28.74M	–
Q4 FY2022	Dec 31, 2022	-$27.40M	–
Q3 FY2022	Sep 30, 2022	-$45.06M	–
Q2 FY2022	Jun 30, 2022	-$42.35M	–
Q1 FY2022	Mar 31, 2022	-$27.67M	–
Q4 FY2021	Dec 31, 2021	-$21.86M	–
Q3 FY2021	Sep 30, 2021	-$34.09M	–
Q2 FY2021	Jun 30, 2021	-$29.62M	–
Q1 FY2021	Mar 31, 2021	-$23.03M	–
Q4 FY2020	Dec 31, 2020	-$15.57M	–
Q3 FY2020	Sep 30, 2020	-$14.56M	–
Q2 FY2020	Jun 30, 2020	-$16.21M	–
Q1 FY2020	Mar 31, 2020	-$10.92M	–